Sign in
Protocol U: Short-Term Evaluation of Combination Dexamethasone + Ranibizumab vs. Ranibizumab Alone for Persistent Central-Involv
Raj K. Maturi, MD
Updates from the Field
2017
Wieland-Khanani Port Delivery System
Mark R. Wieland, MD
Arshad M. Khanani, MD, MA, FASRS
Patients Ultra-Responsive to Ranibizumab (RBZ): Rates of Great Than or Equal to 4-Step Improvement in Diabetic Retinopathy Severity in DRCR.net Protocol S
Allen Chiang, MD, FASRS
Annual Meeting Talks
2019
Category: wet AMD